Table 3 summary of the studies with inconclusive results about the use of IVIG in COVID-19
From: Potential therapeutic approach of intravenous immunoglobulin against COVID-19
Studies with inconsistent results | Type of Study | Number of Cases | Dosage of IVIG | Measurement of treatment success | Other therapies used in the course of disease | Comorbidities | Additional Explanations |
|---|---|---|---|---|---|---|---|
Shao et al. [40] | multicenter retrospective cohort | 325 | 0.1 to 0.5Â g/kg per day for 5 to 15Â days | 28Â day mortality, 60Â day mortality, length of hospital stay, length of disease period | Supportive care | Varied | IVIG therapy cannot reduce the total duration of the disease, only patients with severe COVID-19 from the IVIG group had better 28-day mortality rates |
Tabarsi et al. [54] | Randomized control trial | 84 | 400Â mg/kg/day for three days | In hospital mortality rate, mechanical ventilation need, length of hospital stay | hydroxychloroquine, lopinavir/ritonavir and supportive care | Varied | No improvement in CT scan or the overall course of the disease was observed despite a reduction in the duration of hospitalization |